CiaoTech - PNO Group is partner of the project ONCOVALUE – “Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time” with ttopstart affiliated party, started on December 1st, 2022, and funded by the European Union’s Horizon Europe research and innovation programme under grant agreement No 101095245.

ONCOVALUE’s main objective is to build up data collection and processing capabilities of leading European cancer hospitals to create a high-quality clinical, quality of life, and adverse events data-sources. With the use powerful AI technologies, ONCOVALUE will transform unstructured data into structured data to enable analytics and real-world evidence, directly available for clinicians for treatment management and for health regulatory and HTA bodies to adopt optimized data-driven methodologies for the effective assessment of medicinal products and digital health innovations.

The consortium met on February 8 and 9, 2023 to discuss the project workplan for the next 48 months and present the activities to be carried out in each Work Package.

For ONCOVALUE, CiaoTech is responsible of the Work Package 7, Dissemination, exploitation, and sustainability of the project outcomes and results and is supporting the Work Package 8, Project Management activities with the involvement of ttopstart.